Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (August 2026)
8 slides from Bayer's technical presentation, Aug 29, 2026
Slide 1: Systolic blood pressure variability and effect of finerenone treatment in CKD and T2D: a FIDELITY analysis
83928 Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis Sanjay Rajagopalan, MD; Peter Rossing, MD; Bertram Pitt, MD; Stefan D. Anker, MD, PhD; Gerasimos Filippatos, MD; Zihe Zheng, PhD; Charlie Scot
Slide 2: High visit-to-visit SBP variability is associated with increased risk of CV events and CKD
High visit-to-visit SBP variability is associated with increased risk of CV events and CKD1–8 Increased long-term SBP variability was associated with all-cause mortality and CV events in a meta-analysis of 36 cohorts9 Patients with higher visit-to-visit SBP variability had a 2.1-fold increase (95% C
Slide 3: Study design and key outcomes
Study design and key outcomes Background: SBP variability was measured at: Finerenone, a selective nonsteroidal MRA, reduced the • Pre-treatment: SBP at pre-screening, screening, and baseline risk of adverse CV and kidney outcomes vs placebo in • Post-treatment: SBP every 4 months up to 1 year from
Slide 4: Higher pre-treatment SBP variability increased the risk of composite outcomes
Higher pre-treatment SBP variability increased the risk of composite CV and kidney outcomes Effect of pre- and post-treatment SBP variability on the risk of CV and kidney outcomes Pre-treatment Post-treatment Higher pre-treatment SBP variability increased the likelihood of composite CV and kidney ev
Slide 5: Pre-treatment SBP variability: The treatment effect of finerenone was consistent and unmodified
Pre-treatment SBP variability: The treatment effect of finerenone was consistent and unmodified across SBP variability quartiles Composite CV outcome In patients with high pre-treatment SBP variability, a trend was observed in favour of finerenone for a reduced risk of Composite kidney outcome Favou
Slide 6: Post-treatment SBP variability: The treatment effect of finerenone was consistent and unmodified
Post-treatment SBP variability: The treatment effect of finerenone was consistent and unmodified across SBP variability quartiles In patients with higher post-treatment SBP Composite CV outcome variability, a trend was observed in favour of finerenone for a reduced risk of composite kidney outcomes
Slide 7: Rates of TEAEs and hyperkalaemia were not significantly different
Rates of TEAEs and hyperkalaemia were not significantly different across SBP variability quartiles % of TEAEs and serious TEAEs across treatment groups Any TEAE Any serious TEAE Hyperkalaemia 100 Rates of TEAEs and serious 80 TEAEs were similar between % of patients treatment arms and across SBP 60
Slide 8: Conclusions
Conclusions Higher SBP Finerenone Hyperkalaemia and variability lowered the risk of TEAEs were similar (expressed as SD, CV and kidney across treatment CoV, and VIM) was outcomes vs placebo arms and SBP associated with irrespective of SBP variability quartiles, increased risk of CV variability, and